In May 2026, the medical aesthetics industry continued to tighten its regulations, and normalized and refined supervision was fully implemented. The upstream licensing dividend faded, and small and medium-sized institutions in the midstream accelerated their exit. The industry bid farewell to extensive expansion and entered a new stage of value competition driven by technology, service, and brand.